“Asthma Devices Market” Report is added on MarketReseacrhFuture.com with exhaustive Study. The report aims to provide an overview of Asthma Devices Market Report. The report provides key statistics on the market status. Outlet till 2023
Asthma Devices Market – Overview
The Global Asthma Devices Market is growing moderately. Factors affecting market growth positively are rising prevalence of chronic respiratory disease and increasing usage of combination therapy. The Global Asthma Devices Market is expected to grow at an approximate CAGR of 4.3% during the forecast period.
Asthma is a type of chronic lung disease that inflames and narrows the airways. The symptoms of the disease are inclusive of recurring periods of wheezing, shortness of breath, chest tightness, and coughing. Asthma inhalers are the medical devices which deliver medication to the patient’s body via the lungs. Increasing prevalence of asthma and rising healthcare expenditures are the major drivers for the market growth.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1624
According to the World Health Organization in 2017, approximately 235 million people suffer from asthma. Moreover, it was estimated that in 2015, the disease killed approximately 383 million patients around the globe. However, long treatment procedures and low per capita income followed by lack of favorable reimbursement policies in the developing countries will restrain the market growth during the forecast period.
Asthma Devices Market – Key Players
GlaxoSmithKline plc. (Europe), Merck & Co., Inc. (U.S.), 3M (U.S.), Aristopharma Ltd. (Asia Pacific), SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific), AstraZeneca (Europe), Baxter. (U.S.), Boehringer Ingelheim GmbH (Europe), Koninklijke Philips N.V. (Europe), and others.
Asthma Devices Market – Industry Updates
Feb, 2017 BI received expansion of FDA approval of the use of Tiotropium Respimat for treatment of Asthma in Children. With this approval, company will be able to sell the product inside the United States.
Jan, 2017 AstraZeneca had announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.
Nov, 2016 Chiesi acquires Atopix therapeutics. The acquisition of the UK based clinical stage biotechnology company will help Chiesi enhance its Asthma Segment.
Feb, 2015 AstraZeneca and Actavis Plc had signed agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above certain revenue threshold.
Asthma Devices Market – Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/1624
Asthma Devices Market – Segmentation
The Global Asthma Devices Market is segmented on the basis of type, technology, and end-users.
On the basis of the type, the market is segmented into inhalers, nebulizers, and others. The inhalers segment is sub-segmented into metered-dose inhalers and dry powder inhalers. The metered-dose inhalers segment, by inhalers, is further categorized into standard pressurized metered-dose inhalers, breath-activated pressurized metered-dose inhalers, metered-dose inhalers with a spacer, and others. The nebulizers segment is sub-segmented compressor nebulizers, ultrasonic nebulizers, mesh nebulizers, and others.
On the basis of the technology, the market is segmented into manually operated inhaler devices, digitally operated inhaler devices, and others.
On the basis of the end users, the market is segmented into hospital, clinics, retail pharmacies, and others.
Asthma Devices Market – Regional Analysis
Depending on geographic region, Globally North America is the largest market for Asthma Inhalers. Currently there are around 6.4% of American suffering from COPD in U.S. and around 5.4 million people suffering from asthma in U.K. This major growth is attributed to the increasing demand of the dry powder inhalers among population due to its several advantages over Metered Dose Inhalers and other types of inhalers.
Europe is the second-largest market for asthma inhalers. It is observed that approximately 70% of the child’s death occurs per year are due to respiratory disorders which are results of the sudden attacks hence rescue medication or rescue inhalers can serve better to save lots of lives per year.
Asia pacific region is expected to be fastest growing region in respiratory Inhaler market. Middle East & Africa is expected to have limited but steady growth in the market. These countries with the advancement of technology are expected to show large number of cases of asthma and other respiratory disease which remain unnoticed currently.
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
Get Prime Discount at https://www.marketresearchfuture.com/check-discount/1624
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312